SynKIR-310 for Relapsed/Refractory B-NHL

NCT06544265 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

B Cell Lymphoma
NHL, Adult
Mantle Cell Lymphoma
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Aggressive B-Cell Non-Hodgkin Lymphoma
Indolent B-Cell Non-Hodgkin Lymphoma
Follicular Lymphoma
Marginal Zone Lymphoma
DLBCL - Diffuse Large B Cell Lymphoma
HGBL With MYC and BCL2 and/or BCL6 Rearrangements
High-grade B-cell Lymphoma
Diffuse Large B Cell Lymphoma
Large B-cell Lymphoma
T-Cell/Histiocyte Rich Lymphoma
Non-hodgkin Lymphoma,B Cell
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Epstein-Barr Virus Positive DLBCL, Nos
Follicular Lymphoma Grade 3B
DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation
High Grade B-Cell Lymphoma, Not Otherwise Specified
Follicular Lymphoma Grade 3
Marginal Zone Splenic Lymphoma
DLBCL
Waldenstrom Macroglobulinemia
Waldenstrom Macroglobulinaemia

Interventions

BIOLOGICAL: SynKIR-310

Sponsor

Verismo Therapeutics